
Strong Phase III results have seen the US FDA approve Roche’s Gazyva (obinutuzumab) plus Levact (bendamustine) chemotherapy followed by Gazyva …

Ignyta has acquired four oncology R&D assets from Israeli pharma generics giant Teva in a deal worth around $42 million. …

Roche and Amgen have both posted successful late-stage trial results that they say will contribute to their applications for regulatory …
A treatment for patients with the most common form of leukaemia has been fast tracked by NICE because of strong …


